MEK inhibitors are mainly used in BRAF mutant colorectal cancer patients in combination with BRAF inhibitors or other drugs to enhance efficacy and delay resistance (Ros et al., 2021; Sullivan et al., 2015). Here, MAP2K7 is linked to colorectal cancer.